Skip to main content
. 2016 Jan 31;7(10):11137–11150. doi: 10.18632/oncotarget.7097

Figure 4. Evidence for a M2 activation phenotype of CD11b+ cells in the blood of metastatic breast cancer patients.

Figure 4

(A) Quantification of the mRNA expression levels of M2 markers CD163, (B) ARG1 and (C) IL-10 in CD11b+ cells derived from the blood of healthy donors compare to cancer patients before therapy start. (D) Quantification of mRNA expression levels of M1 markers CCR7, (E) CD86 and (F) IL-12α at mRNA level in CD11b+ cells of the same healthy donors and cancer patients. Analysis was performed by real time qPCR. All data are represented as mean +/− SD.